KIMIA FARMA -B-
PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia, rest of Asia, Europe, Australia, Africa, and New Zealand. The company operates through Manufacturing, Distribution, Retail, and Other Services segments. It also manufactures and markets chemical, betalactam and non betalactam, antiretr… Read more
KIMIA FARMA -B- (HQP) - Net Assets
Latest net assets as of June 2025: €3.29 Trillion EUR
Based on the latest financial reports, KIMIA FARMA -B- (HQP) has net assets worth €3.29 Trillion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€14.97 Trillion) and total liabilities (€11.68 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.29 Trillion |
| % of Total Assets | 21.99% |
| Annual Growth Rate | 5.28% |
| 5-Year Change | -51.75% |
| 10-Year Change | N/A |
| Growth Volatility | 47.69 |
KIMIA FARMA -B- - Net Assets Trend (2016–2024)
This chart illustrates how KIMIA FARMA -B-'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for KIMIA FARMA -B- (2016–2024)
The table below shows the annual net assets of KIMIA FARMA -B- from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.43 Trillion | -28.24% |
| 2023-12-31 | €4.78 Trillion | -40.29% |
| 2022-12-31 | €8.00 Trillion | +35.88% |
| 2021-12-31 | €5.89 Trillion | -17.12% |
| 2020-12-31 | €7.11 Trillion | -4.14% |
| 2019-12-31 | €7.41 Trillion | +120.86% |
| 2018-12-31 | €3.36 Trillion | +30.47% |
| 2017-12-31 | €2.57 Trillion | +13.26% |
| 2016-12-31 | €2.27 Trillion | -- |
Equity Component Analysis
This analysis shows how different components contribute to KIMIA FARMA -B-'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1598.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €7.43 Trillion | 323.94% |
| Total Equity | €2.29 Trillion | 100.00% |
KIMIA FARMA -B- Competitors by Market Cap
The table below lists competitors of KIMIA FARMA -B- ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
American Well Corp
NYSE:AMWL
|
$78.62 Million |
|
Neptune Digital Assets Corp
PINK:NPPTF
|
$78.64 Million |
|
Shoprite Holdings Ltd
JSE:SHP
|
$78.73 Million |
|
Orient Cement Limited
NSE:ORIENTCEM
|
$78.76 Million |
|
PATRIOT BANK DL 2
F:PN21
|
$78.57 Million |
|
MPS Limited
NSE:MPSLTD
|
$78.56 Million |
|
Softstar Entertainment
TWO:6111
|
$78.55 Million |
|
Frontier Lithium Inc
OTCQX:LITOF
|
$78.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in KIMIA FARMA -B-'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,178,135,996,000 to 2,293,469,732,000, a change of -884,666,264,000 (-27.8%).
- Net loss of 842,272,199,000 reduced equity.
- Dividend payments of 78,623,000 reduced retained earnings.
- Other factors decreased equity by 42,315,442,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-842.27 Billion | -36.72% |
| Dividends Paid | €78.62 Million | -0.0% |
| Other Changes | €-42.32 Billion | -1.85% |
| Total Change | €- | -27.84% |
Book Value vs Market Value Analysis
This analysis compares KIMIA FARMA -B-'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €451.98 | €0.14 | x |
| 2018-12-31 | €576.52 | €0.14 | x |
| 2019-12-31 | €1303.91 | €0.14 | x |
| 2020-12-31 | €1259.16 | €0.14 | x |
| 2021-12-31 | €1043.79 | €0.14 | x |
| 2022-12-31 | €1036.48 | €0.14 | x |
| 2023-12-31 | €572.22 | €0.14 | x |
| 2024-12-31 | €412.01 | €0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently KIMIA FARMA -B- utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.47%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 6.53x
- Recent ROE (-36.72%) is below the historical average (-6.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 12.04% | 4.60% | 1.26x | 2.08x | €45.32 Billion |
| 2017 | 13.02% | 5.33% | 1.01x | 2.43x | €75.76 Billion |
| 2018 | 12.99% | 5.58% | 0.79x | 2.95x | €95.70 Billion |
| 2019 | -0.18% | -0.14% | 0.51x | 2.53x | €-736.91 Billion |
| 2020 | 0.25% | 0.18% | 0.57x | 2.51x | €-681.70 Billion |
| 2021 | 5.21% | 2.35% | 0.75x | 2.97x | €-277.45 Billion |
| 2022 | -3.31% | -2.06% | 0.47x | 3.44x | €-766.14 Billion |
| 2023 | -61.80% | -19.90% | 0.59x | 5.23x | €-2.28 Trillion |
| 2024 | -36.72% | -8.47% | 0.66x | 6.53x | €-1.07 Trillion |
Industry Comparison
This section compares KIMIA FARMA -B-'s net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $17,949,088,624
- Average return on equity (ROE) among peers: -105.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| KIMIA FARMA -B- (HQP) | €3.29 Trillion | 12.04% | 3.55x | $78.59 Million |
| Asker Healthcare Group AB (I88) | $3.50 Billion | 10.28% | 2.75x | $1.37 Billion |
| Paragon Care Limited (PXS) | $18.21 Million | 5.96% | 0.48x | $52.86 Million |
| TELES Informationstechnologien AG (TLIK) | $379.23K | -446.97% | 3.69x | $801.14K |
| Sinopharm Group Co. Ltd (X2S) | $68.28 Billion | 8.55% | 2.45x | $3.27 Billion |